Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2022-09-02 00:00:00 ET · period of report 2022-09-01 · accession 0001209191-22-048472 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-02 | 2022-09-01 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | A - Grant | $0.00 | +7,500 | 85.2K | +10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-01 | A | A | 7,500 | $0.00 | 85,246 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. (F2) Includes 1,151 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022. |